Selected Grants
DNA11 Argenx 999-2-MG-2000 Platform Study ISA Protocol
Clinical TrialPrincipal Investigator · Awarded by Argenx BV · 2026 - 2036A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Clinical TrialPrincipal Investigator · Awarded by Argenx BV · 2026 - 2035Capture MG
ResearchPrincipal Investigator · Awarded by The George Washington University · 2025 - 2030DNA08: ARGX-113-2315
Clinical TrialPrincipal Investigator · Awarded by Argenx BVBA · 2025 - 2030DNA05 Argenx_ARGX-113-2308: A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab)
Clinical TrialPrincipal Investigator · Awarded by Argenx BVBA · 2024 - 2029Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies
ResearchPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2020 - 2026Deciphering Immunological Biomarkers in Myasthenia Gravis by Using Multi-omics
ResearchSignificant Contributor · Awarded by Myasthenia Gravis Foundation · 2024 - 2026Alexion ALXN1720-MG-301
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2023 - 2026RARE DISEASE NETWORK FOR MYASTHENIA GRAVIS (Career Enhancement)
ResearchPrincipal Investigator · Awarded by The George Washington University · 2024 - 2025NIMBLE-Rare Disease Network for Myasthenia Gravis
ResearchPrincipal Investigator · Awarded by The George Washington University · 2021 - 2025RARE DISEASE NETWORK FOR MYASTHENIA GRAVIS (Site Agreement)
ResearchPrincipal Investigator · Awarded by The George Washington University · 2019 - 2025RARE DISEASE NETWORK FOR MYASTHENIA GRAVIS
ResearchPrincipal Investigator · Awarded by The George Washington University · 2021 - 2024A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naive Adult Patients with Generalized Myasthenia Gravis
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2019 - 2023RARE DISEASE NETWORK FOR MYASTHENIA GRAVIS (ADAPT)
ResearchPrincipal Investigator · Awarded by The George Washington University · 2020 - 2023PROMISE-MG: PROSPECTIVE MULTICENTER OBSERVATIONAL COHORT STUDY OF COMPARATIVE EFFECTIVENESS OF DISEASE-MODIFYING TREATMENTS FOR MYASTHENIA GRAVIS
ResearchPrincipal Investigator · Awarded by Patient-Centered Outcomes Research Institute · 2017 - 2021VTEU Task C Option 1 Protocol 14-0024.C1D1.0037
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2018 - 2020VTEU Task C Base Protocol 14-0024.C1D1.0037
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2015 - 2020VTEU Task D Option 2 Protocol 14-0024.C1D1.0037
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2015 - 2020VTEU Task D Option 5 Protocol 14-0024.C1D1.0037
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2015 - 2020VTEU Task D Option 4 Protocol 14-0024.C1D1.0037
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2015 - 2020A Phase III, Open Label,Extension Trial of ECU-MG-301 to evaluate the Safety and Efficacy of Eculizumab in subjects with Refractory Generalized Myasthenia Gravis
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2014 - 2019VTEU Task D Option 3 Protocol 14-0024.C1D1.0037
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2015 - 2019AANEM Autoimmune Neuromuscular Disorders Fellowship
FellowshipAdvisor · Awarded by AANEM Foundation for Research & Education · 2017 - 2018A Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects with Generalized Refractory Myasthenia Gravis (GMG)
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2014 - 2017External Relationships
- Alexion Pharmaceuticals, Inc. a subsidiary of AstraZeneca
- Immunovant
- argenx US, Inc
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.